The mycobacterial mystery

European Respiratory Journal

Volumn 28, Issue 6, 2006, Pages 1076-1078

  Schonfeld N ^a  

^a HELIOS KLINIKUM EMIL VON BEHRING   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; RIFAMPICIN;

ANTIBIOTIC SENSITIVITY; BACTERIAL COLONIZATION; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BRONCHIECTASIS; DRUG BLOOD LEVEL; DRUG PENETRATION; EDITORIAL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; MEDICAL LITERATURE; MEDICAL RESEARCH; MEDICAL SOCIETY; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; MYCOBACTERIUM MALMOENSE; MYCOBACTERIUM XENOPEI; PATHOGENESIS; PRIORITY JOURNAL;

BRONCHIECTASIS; HUMANS; MYCOBACTERIA, ATYPICAL; MYCOBACTERIUM INFECTIONS;

EID: 33845354042     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.00113006     Document Type: Editorial

References (18)

1. Shafran SD, Singer J, Zarowny DP, et al. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. N Engl J Med 1996; 335: 377-383.
2. May T, Brel F, Beuscart C, et al. Comparison of combination therapy regimens for treatment of human immunodeficiency virus-infected patients with disseminated bacteremia due to Mycobacterium avium. ANRS Trial 033 Curavium Group. Agence Nationale de Recherche sur le Sida. Clin Infect Dis 1997; 25: 621-629.
3. Field SK, Cowie RL. Lung disease due to the more common nontuberculous mycobacteria. Chest 2006; 129: 1653-1672.
4. Wolinsky E. Nontuberculous mycobacteria and associated diseases. Am Rev Respir Dis 1979; 119: 107-159.
5. Radenbach KL. Diagnostische und therapeutische Fortschritte bei nichttuberkulösen Mykobakteriosen. [Diagnostic and therapeutic progress in nontuberculous mycobacterioses.]. Prax Klin Pneumol 1985; 39: 43-49.
6. American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med 1997; 156: S1-S25.
7. Subcommittee of the joint Tuberculosis Committee of the British Thoracic Society. Management of the opportunistic mycobacterial infections, Joint Tuberculosis Committee guidelines 1999. Thorax 2000; 55: 210-218.
8. Dailloux M, Abalain ML, Laurain C, et al. and the French Mycobacteria Study Group. Respiratory infections associated with nontuberculous mycobacteria in non-HIV patients. Eur J Respir 2006; 28: 1211-1215.
9. Fowler SJ, French J, Screaton NJ, et al. Nontuberculous mycobacteria in bronchiectasis: prevalence and patient characteristics. Eur J Respir 2006; 28: 1204-1210.
10. Woods GL. Susceptibility testing for mycobacteria. Clin Infect Dis 2000; 31: 1209-1215.
11. Gößwald A. Klinik, Diagnostik, Therapie und Verlauf pulmonaler Infektionen durch nichttuberkulöse Mykobakterien bei HIV-negativen Patienten in Berlin 1986-1998. Diss. med., Freie Universität, Berlin, 2004.
12. Roth A, Reischl U, Schönfeld N, et al. Mycobacterium heckeshornense sp. nov., a new pathogenic slowly growing Mycobacterium sp. causing cavitary lung disease in an immunocompetent patient. J Clin Microbiol 2000; 38: 4102-4107.
13. Research Committee of the British Thoracic Society. First randomised trial of treatments for pulmonary disease caused by M. avium intracellulare, M. malmoense, and M. xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol. Thorax 2001; 56: 167-172.
14. Bass JB, Farer LS, Hopewell PC, et al. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention. Am J Respir Crit Care Med 1994; 149: 1359-1374.
15. Rodriguez Diaz JC, Lopez M, Ruiz M, Royo G. In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria. Int J Antimicrob Agents 2003; 21: 585-588.
16. Aragon LM, Navarro F, Heiser V, Garrigo M, Espanol M, Coll P. Rapid detection of specific gene mutations associated with isoniazid or rifampicin resistance in Mycobacterium tuberculosis clinical isolates using non-fluorescent low-density DNA microarrays. J Antimicrob Chemother 2006; 57: 825-831.
17. Doffinger R, Patel SY, Kumararatne DS. Host genetic factors and mycobacterial infections: lessons from single gene disorders affecting innate and adaptive immunity. Microbes Infect 2006; 8: 1141-1450.
18. Oliveira RS, Sircili MP, Oliveira EMD, Balian SC, Ferreira-Neto JS, Leão SC. Identification of Mycobacterium avium genotypes with distinctive traits by combination of IS1245-based restriction fragment length polymorphism and restriction analysis of hsp65. J Clin Microbiol 2003; 41: 44-49.